1) Strategy & Leadership - Jacob Steven Leach, President and CEO, emphasized DexCom's focus on expanding its glucose sensing solutions, particularly for type 2 diabetes patients who are not on insulin. - The company is working towards achieving comprehensive coverage for all diabetes patients, with a significant milestone being the upcoming coverage from Prime Therapeutics for over 7 million type 2 non-insulin lives. - DexCom is preparing for its Investor Day, where it will discuss its growth strategies, including the launch of new products and enhancements to customer experience.

2) Financial & Segment Results - Q1 2026 revenue reached $1.19 billion, a 15% increase YoY, with organic growth at 12%. - U.S. revenue was $832 million, up 11% YoY, while international revenue grew 26% to $360 million, with organic growth at 17%. - Gross profit margin improved to 63.5%, up from 57.5% YoY, and operating income was $264.4 million, representing 22.2% of revenue. - Net income for the quarter was $216.3 million, or $0.56 per share, marking a 75% increase YoY.

3) Operational & Product Plans - The launch of the DexCom G7 15-day system has been well-received, with nearly 50% of the existing customer base expected to convert to this product by year-end. - DexCom is also working on a new patch technology and software updates, including a redesign of the Stello app to enhance user experience and engagement. - The company is conducting a randomized control trial for type 2 diabetes patients not on insulin, with results expected to be shared at the ADA's 2026 Scientific Sessions.

4) Guidance & Outlook - DexCom reaffirmed its full-year revenue guidance of $5.16 billion to $5.20 billion, anticipating growth of 11% to 13%. - The company raised its non-GAAP operating profit margin guidance to 23% to 23.5% and adjusted EBITDA margin guidance to 31% to 31.5%. - Despite maintaining gross margin guidance due to geopolitical uncertainties, the company remains optimistic about its operational efficiencies and cash flow generation.

5) Problems / Headwinds - The company acknowledged potential headwinds from inflation affecting gross margins, particularly related to fuel and resin costs, which could impact margins by 50 to 100 basis points. - There is uncertainty regarding the timing of CMS coverage for the type 2 non-insulin population, which is seen as a critical growth driver.

Bottom line: DexCom is positioned for continued growth with strong Q1 results and strategic initiatives aimed at expanding market access and enhancing customer experience. The upcoming coverage expansions and product launches, particularly in the type 2 diabetes segment, are expected to drive future performance, despite some inflationary pressures and uncertainties in regulatory approvals.